ArticleJournal of market access & health policy2021
Cost-Effectiveness Analysis of a Prescription Digital Therapeutic for the Treatment of Opioid Use Disorder.
Article in Journal of market access & health policy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Digitally Delivered Cognitive Behavioral Interventions for Alcohol and Other Drug Use: Meta-Analysis Across Consumption and Psychosocial Outcomes.JMIR mental health · 2026Pooled it
- Health economic evaluations of digital health technologies-a rapid review of applied methods.Frontiers in digital health · 2026Review
- Economic cost of strategic implementation approaches to increase uptake of digital therapeutics for substance use disorders in a large integrated health system.PLOS digital health · 2026Article
- Economic Impact of an Employer-Sponsored Integrated Digital Intervention Targeting Substance Use Disorders: Return on Investment Analysis.Telemedicine journal and e-health : the official journal of the American Telemedicine Association · 2025Article
- Approved trends and product characteristics of digital therapeutics in four countries.NPJ digital medicine · 2025Article
- Download to heal: navigating the pixelated path of digital therapeutics in psychiatric care.Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999) · 2025Review
- Redesigning Pharmacy to Improve Public Health Outcomes: Expanding Retail Spaces for Digital Therapeutics to Replace Consumer Products That Increase Mortality and Morbidity Risks.Pharmacy (Basel, Switzerland) · 2024Article
- Estimating and Rewarding the Value of Healthcare Interventions Beyond the Healthcare Sector: A Conceptual Framework.PharmacoEconomics · 2024Article
- Digital Therapeutics for Improving Effectiveness of Pharmaceutical Drugs and Biological Products: Preclinical and Clinical Studies Supporting Development of Drug + Digital Combination Therapies for Chronic Diseases.Journal of clinical medicine · 2024Review
- Adoption of Digital Therapeutics in Europe.Therapeutics and clinical risk management · 2024Review
- Cost-effectiveness of digital therapeutics for essential hypertension.Hypertension research : official journal of the Japanese Society of Hypertension · 2022Article
- Adjunct Digital Interventions Improve Opioid-Based Pain Management: Impact of Virtual Reality and Mobile Applications on Patient-Centered Pharmacy Care.Frontiers in digital health · 2022Review
- Health educationFrontiers in public health · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The lack of adequate treatment for many patients with opioid use disorder (OUD) has led to high medical costs ($90B in 2020). An analysis of the cost-effectiveness (cost-utility) of reSET-O, the first and only FDA-approved prescription digital therapeutic (PDT) for the treatment of OUD, is needed to inform value assessments and healthcare decision making. To evaluate the cost-utility of reSET-O in conjunction with treatment-as usual (TAU) compared to TAU alone. A third-party payer-perspective decision analytic model evaluated the cost-effectiveness of reSET-O + TAU relative to TAU (i.e., oral buprenorphine, face-to-face counseling, and contingency management [immediate rewards for negative drug tests logged]) alone over 12 weeks. Clinical effectiveness data (retention in therapy and health state utilities) were obtained from the peer-reviewed literature, while resource utilization and cost data were obtained from a published claims data analyses. Over 12 weeks, the addition of reSET-O to TAU resulted in a gain of 0.003 quality-adjusted life years (QALYs), and $1,014 lower costs, resulting in economic dominance vs. TAU. reSET-O + TAU's was economically dominant (less costly, more effective) vs. TAU alone over 12 weeks, a result that was driven by a reduction in medical costs after initiation of reSET-O observed in a recent real-world claims analysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.